Kietiburanakul et al developed a score for predicting the risk of an HIV-positive patient developing a skin rash in association with nevirapine therapy. An alternative drug may be considered for a patient who has high risk for developing a rash with nevirapine The authors are from Mahidol University in Bangkok, Thailand.
Patient selection: HIV-positive patient with low CD4 count treated with nevirapine in a resource limited setting
Parameters:
(1) history of drug allergy
(2) body weight in kilograms
(3) dose escalation regimen
(4) number of concomitant drugs (type not defined)
Parameter |
Finding |
Points |
history of drug allergy |
no |
0 |
|
yes |
14 |
body weight in kilograms |
<= 55 kg |
7 |
|
> 55 k |
0 |
dose escalation |
slow |
0 |
|
not slow |
7 |
number of concomitant drugs |
0 |
9 |
|
1 or more |
0 |
total score =
= SUM(points for all 4 parameters)
Interpretation:
• minimum score: 0
• maximum score 37
• A score >= 21 identifies a patient at high risk for developing a rash (odds ratio 4).
• A positive score is achieved with history of drug allergy and at least one other risk factor OR the 3 risk factors other than history of drug allergy.
Perfromance:
• The specificity of a positve score was 99% with a positive predictive value of 69%. The sensitivity was not given but it is very low if read from Figure 1.
• The area under the ROC curve was 0.71 which is mediocre.
Purpose: To identify an HIV-positive patient with low CD4 count who is at high risk for developing a rash if started on nevirapine.
Specialty: Dermatology, Pharmacology, clinical
Objective: risk factors, options, adverse effects
ICD-10: B24, T37.8,